Overview

Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
Phase:
Phase 1
Details
Lead Sponsor:
Reza Dana, MD
Treatments:
Ranibizumab